Background/History
Business Model and Strategy
Leadership
Board of Directors
Scientific Advisory Board
Fact Sheet
Licensing Agreement
Medical Coatings
Pharmaceutical R & D
Licensing Agreement 

NUCRYST's strategy is to maximize its return on investment by collaborating with industry leaders to gain the benefits of their global market presence while avoiding the direct costs of developing its own sales and marketing capabilities.

Advanced wound care products with NUCRYST's SILCRYST™ coating are marketed, sold and distributed globally in 30 countries by Smith & Nephew under its Acticoat™ trademark. Smith & Nephew is a global medical device company, with total reported sales of approximately $2.6 billion in 2005.

NUCRYST invented and manufactures Acticoat™ antimicrobial barrier dressings for serious wounds including burns and chronic wounds using its patented coating with SILCRYST™ nanocrystals.

For more information about Acticoat™ antimicrobial barrier dressings, please visit Smith & Nephew's www.acticoat.com site. For more information about NUCRYST's licensing agreement with Smith & Nephew, click here.